115 related articles for article (PubMed ID: 38293743)
21. Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo.
Li Q; Ding Y; Guo X; Luo S; Zhuang H; Zhou J; Xu N; Yan Z
J Cell Mol Med; 2019 Mar; 23(3):1951-1962. PubMed ID: 30592139
[TBL] [Abstract][Full Text] [Related]
22. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.
Wang Y; Gao J; Zhang D; Zhang J; Ma J; Jiang H
J Hepatol; 2010 Jul; 53(1):132-44. PubMed ID: 20447716
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib-loaded silica-containing redox nanoparticles for oral anti-liver fibrosis therapy.
Tran HT; Vong LB; Nishikawa Y; Nagasaki Y
J Control Release; 2022 May; 345():880-891. PubMed ID: 35395328
[TBL] [Abstract][Full Text] [Related]
24. Fibronectin Type III Domain-Containing 5 Attenuates Liver Fibrosis Via Inhibition of Hepatic Stellate Cell Activation.
Zhou B; Ling L; Zhang F; Liu TY; Zhou H; Qi XH; Chen Q; Li YH; Kang YM; Zhu GQ
Cell Physiol Biochem; 2018; 48(1):227-236. PubMed ID: 30007970
[TBL] [Abstract][Full Text] [Related]
25. The herbal compound Songyou Yin (SYY) inhibits hepatocellular carcinoma growth and improves survival in models of chronic fibrosis via paracrine inhibition of activated hepatic stellate cells.
Bu Y; Jia QA; Ren ZG; Xue TC; Zhang QB; Zhang KZ; Zhang QB; You Y; Tian H; Qin LX; Tang ZY
Oncotarget; 2015 Nov; 6(37):40068-80. PubMed ID: 26517671
[TBL] [Abstract][Full Text] [Related]
26. The combined induction of liver progenitor cells and the suppression of stellate cells by small molecules reverts chronic hepatic dysfunction.
Huang WJ; Zhou X; Fu GB; Ding M; Wu HP; Zeng M; Zhang HD; Xu LY; Gao Y; Wang HY; Yan HX
Theranostics; 2021; 11(11):5539-5552. PubMed ID: 33859762
[No Abstract] [Full Text] [Related]
27. Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell.
Zhang H; Sun D; Wang G; Cui S; Field RA; Li J; Zang Y
Biochem Biophys Res Commun; 2019 Apr; 511(2):387-393. PubMed ID: 30797555
[TBL] [Abstract][Full Text] [Related]
28. The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis.
Kumar V; Dong Y; Kumar V; Almawash S; Mahato RI
Theranostics; 2019; 9(25):7537-7555. PubMed ID: 31695785
[No Abstract] [Full Text] [Related]
29. Oral vitamin-A-coupled valsartan nanomedicine: High hepatic stellate cell receptors accessibility and prolonged enterohepatic residence.
El-Mezayen NS; El-Hadidy WF; El-Refaie WM; Shalaby TI; Khattab MM; El-Khatib AS
J Control Release; 2018 Aug; 283():32-44. PubMed ID: 29792888
[TBL] [Abstract][Full Text] [Related]
30. P2X7R orchestrates the progression of murine hepatic fibrosis by making a feedback loop from macrophage to hepatic stellate cells.
Jiang M; Cui BW; Wu YL; Zhang Y; Shang Y; Liu J; Yang HX; Qiao CY; Zhan ZY; Ye H; Jin Q; Nan JX; Lian LH
Toxicol Lett; 2020 Oct; 333():22-32. PubMed ID: 32721574
[TBL] [Abstract][Full Text] [Related]
31. Albumin-Based Silibinin Nanocrystals Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy.
Luo S; Yang Y; Zhao T; Zhang R; Fang C; Li Y; Zhang Z; Gong T
ACS Appl Mater Interfaces; 2023 Feb; 15(6):7747-7758. PubMed ID: 36719351
[TBL] [Abstract][Full Text] [Related]
32. [
Shao T; Chen Z; Belov V; Wang X; Rwema SH; Kumar V; Fu H; Deng X; Rong J; Yu Q; Lang L; Lin W; Josephson L; Samir AE; Chen X; Chung RT; Liang SH
J Hepatol; 2020 Jul; 73(1):161-169. PubMed ID: 32145257
[TBL] [Abstract][Full Text] [Related]
33. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
34. Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis.
Hassan R; Tammam SN; Safy SE; Abdel-Halim M; Asimakopoulou A; Weiskirchen R; Mansour S
Eur J Pharm Biopharm; 2019 Jan; 134():96-106. PubMed ID: 30471341
[TBL] [Abstract][Full Text] [Related]
35. Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling.
Li J; Wang Y; Ma M; Jiang S; Zhang X; Zhang Y; Yang X; Xu C; Tian G; Li Q; Wang Y; Zhu L; Nie H; Feng M; Xia Q; Gu J; Xu Q; Zhang Z
EBioMedicine; 2019 Feb; 40():43-55. PubMed ID: 30639416
[TBL] [Abstract][Full Text] [Related]
36. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway.
Grouix B; Sarra-Bournet F; Leduc M; Simard JC; Hince K; Geerts L; Blais A; Gervais L; Laverdure A; Felton A; Richard J; Ouboudinar J; Gagnon W; Leblond FA; Laurin P; Gagnon L
J Pharmacol Exp Ther; 2018 Oct; 367(1):71-81. PubMed ID: 30093459
[TBL] [Abstract][Full Text] [Related]
37. PDGFRβ-targeted TRAIL specifically induces apoptosis of activated hepatic stellate cells and ameliorates liver fibrosis.
Li R; Li Z; Feng Y; Yang H; Shi Q; Tao Z; Cheng J; Lu X
Apoptosis; 2020 Feb; 25(1-2):105-119. PubMed ID: 31894448
[TBL] [Abstract][Full Text] [Related]
38. Treatment with 4-methylpyrazole modulated stellate cells and natural killer cells and ameliorated liver fibrosis in mice.
Yi HS; Eun HS; Lee YS; Jung JY; Park SH; Park KG; Choi HS; Suh JM; Jeong WI
PLoS One; 2015; 10(5):e0127946. PubMed ID: 26024318
[TBL] [Abstract][Full Text] [Related]
39. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
Zhang Z; Yao Z; Wang L; Ding H; Shao J; Chen A; Zhang F; Zheng S
Autophagy; 2018; 14(12):2083-2103. PubMed ID: 30081711
[TBL] [Abstract][Full Text] [Related]
40. N-n-Butyl haloperidol iodide ameliorates liver fibrosis and hepatic stellate cell activation in mice.
Shen DF; Cheng H; Cai BZ; Cai WF; Wang B; Zhu Q; Wu YB; Liu M; Chen RJ; Gao FF; Zhang YM; Niu YD; Shi GG
Acta Pharmacol Sin; 2022 Jan; 43(1):133-145. PubMed ID: 33758354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
